Horowitz, Mark Abie

The serotonin theory of depression: a systematic umbrella review of the evidence

Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023) · Molecular Psychiatry

Neurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

Cited by 960

Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis

Anacker, C., Cattaneo, A., Musaelyan, K., Zunszain, P. A., Horowitz, M., Molteni, R., Luoni, A., Calabrese, F., Tansey, K., Gennarelli, M., et al. (2013) · Proceedings of the National Academy of Sciences

Neurogenesis and neuroplasticity mechanismsStress Responses and Cortisol

Cited by 319

Tapering of SSRI treatment to mitigate withdrawal symptoms

Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 280

A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse

Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 157

Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression

Nikkheslat, N., Zunszain, P. A., Horowitz, M. A., Barbosa, I. G., Parker, J. A., Myint, A.-M., Schwarz, M. J., Tylee, A. T., Carvalho, L. A., & Pariante, C. M. (2015) · Brain Behavior and Immunity

Stress Responses and CortisolCardiac Health and Mental Health

Cited by 147

Stress abnormalities in individuals at risk for psychosis: A review of studies in subjects with familial risk or with “at risk” mental state

Aiello, G., Horowitz, M., Hepgul, N., Pariante, C. M., & Mondelli, V. (2012) · Psychoneuroendocrinology

Stress Responses and CortisolSchizophrenia research and treatment

Cited by 141

Rescue of IL-1β-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants

Borsini, A., Alboni, S., Horowitz, M. A., Tojo, L. M., Cannazza, G., Su, K.-P., Pariante, C. M., & Zunszain, P. A. (2017) · Brain, Behavior, and Immunity

Tryptophan and brain disordersNeurogenesis and neuroplasticity mechanisms

Cited by 126

Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults

Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews

Treatment of Major DepressionMental Health Treatment and Access

Cited by 90

The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition

Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020) · Therapeutic Advances in Psychopharmacology

Treatment of Major DepressionMental Health Treatment and Access

Cited by 77

Estimating Risk of Antidepressant Withdrawal from a Review of Published Data

Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2023) · CNS Drugs

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 76

Glucocorticoids and Inflammation: A Double-Headed Sword in Depression?

Horowitz, M. A., Zunszain, P. A., Anacker, C., Musaelyan, K., & Pariante, C. M. (2013) · Modern Trends in Psychiatry

Stress Responses and CortisolTryptophan and brain disorders

Cited by 57

Are we repeating mistakes of the past? A review of the evidence for esketamine

Horowitz, M. A., & Moncrieff, J. (2021) · The British Journal of Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 53

Tapering antipsychotic treatment

Horowitz, M. A., Murray, R. M., & Taylor, D. (2021) · JAMA Psychiatry

Schizophrenia research and treatmentBipolar Disorder and Treatment

Cited by 49

Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder

Moncrieff, J., Gupta, S., & Horowitz, M. A. (2020) · Therapeutic Advances in Psychopharmacology

Schizophrenia research and treatmentBipolar Disorder and Treatment

Cited by 43

Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop

Horowitz, M., & Wilcock, M. (2022) · Drug and Therapeutics Bulletin

Treatment of Major DepressionMental Health Treatment and Access

Cited by 33

How to reduce and stop psychiatric medication

Horowitz, M. A., & Taylor, D. (2022) · European Neuropsychopharmacology

Schizophrenia research and treatmentTreatment of Major Depression

Cited by 26

“Stabilise-reduce, stabilise-reduce”: A survey of the common practices of deprescribing services and recommendations for future services

Cooper, R. E., Ashman, M., Lomani, J., Moncrieff, J., Guy, A., Davies, J., Morant, N., & Horowitz, M. (2023) · PLOS ONE

Pharmaceutical Practices and Patient OutcomesOpioid Use Disorder Treatment

Cited by 23

The nature and impact of antidepressant withdrawal symptoms and proposal of the Discriminatory Antidepressant Withdrawal Symptoms Scale (DAWSS)

Moncrieff, J., Read, J., & Horowitz, M. A. (2024) · Journal of Affective Disorders Reports

Treatment of Major DepressionBipolar Disorder and Treatment

Cited by 20

Addiction and physical dependence are not the same thing

Horowitz, M. A., & Taylor, D. (2023) · The Lancet Psychiatry

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 16

Tapering of SSRI treatment to mitigate withdrawal symptoms—authors' reply

Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 15

Identifying priorities for future research on reducing and stopping psychiatric medication: results of a James Lind Alliance priority-setting partnership

Boland, M., Higgins, A., Beecher, C., Bracken, P., Burn, W., Cody, A., Framer, A., Gronlund, T., Horowitz, M., Huff, C., et al. (2024) · BMJ Open

Mental Health and Patient InvolvementMental Health Treatment and Access

Cited by 14

Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study

O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2023) · Therapeutic Advances in Psychopharmacology

Schizophrenia research and treatmentPharmaceutical studies and practices

Cited by 12

Hidden Costs: The Clinical and Research Pitfalls of Mistaking Antidepressant Withdrawal for Relapse

Horowitz, M. A., & Davies, J. (2024) · Psychotherapy and Psychosomatics

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 7

Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs

O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2024) · Therapeutic Advances in Psychopharmacology

Schizophrenia research and treatmentPharmacogenetics and Drug Metabolism

Cited by 7